Literature DB >> 20572907

Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.

Takao Kiriyama1, Hiroshi Kataoka, Toshiaki Taoka, Yasuyo Tonomura, Mari Terashima, Masami Morikawa, Emi Tanizawa, Makoto Kawahara, Yoshiko Furiya, Kazuma Sugie, Kimihiko Kichikawa, Satoshi Ueno.   

Abstract

BACKGROUND AND
PURPOSE: Features of tumefactive demyelinating lesion (TDL) on magnetic resonance imaging (MRI) can facilitate the differential diagnosis of TDL and neoplastic lesions, but vary considerably among patients. The larger TDL grows, the more difficult it becomes to differentiate TDL from neoplastic lesions. The purpose of this study was to elucidate typical MRI features in 12 patients with large TDL (>30 mm in diameter).
METHODS: We identified 12 patients with large TDL (six men, six women; age range 17-64 years, median age 27 years) and studied the clinical histories and the results of laboratory and various radiological studies in these patients. All cases of clinically definite multiple sclerosis were diagnosed in accordance with McDonald's revised criteria.
RESULTS: Common MRI features of large TDLs included variable degrees of mass effect (71%) and edema (100%), a T2 hypointense rim (79%), venular enhancement (57%), and peripheral restriction on diffusion-weighted images (50%). Ring enhancement (38%), open-ring enhancement (31%), or decreased N-acetylaspartate ratios on magnetic resonance spectroscopy (22%) were less frequently observed. Brain angiography demonstrated venous dilatations on and around the TDL.
CONCLUSIONS: The diagnosis of large TDL is challenging. Our findings suggest that multiple venous dilatations on and around TDLs on angiography can facilitate diagnosis.
Copyright © 2010 by the American Society of Neuroimaging.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20572907     DOI: 10.1111/j.1552-6569.2010.00502.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  24 in total

1.  [Inflammatory diseases of the central nervous system].

Authors:  Armin Bachhuber
Journal:  Radiologe       Date:  2021-06-08       Impact factor: 0.635

2.  Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Authors:  A Siri; Clarisse Carra-Dalliere; X Ayrignac; J Pelletier; B Audoin; S Pittion-Vouyovitch; M Debouverie; C Lionnet; F Viala; D Sablot; D Brassat; J-C Ouallet; A Ruet; B Brochet; L Taillandier; L Bauchet; N Derache; G Defer; P Cabre; J de Seze; C Lebrun Frenay; M Cohen; P Labauge
Journal:  J Neurol       Date:  2015-05-01       Impact factor: 4.849

3.  Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.

Authors:  Rocco Totaro; C Di Carmine; A Splendiani; S Torlone; L Patriarca; C Carrocci; S Sciamanna; C Marini; A Carolei
Journal:  Neurol Sci       Date:  2016-04-15       Impact factor: 3.307

4.  Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

Authors:  Mirja Wallner-Blazek; Alex Rovira; Massimo Fillipp; Mara A Rocca; David H Miller; Klaus Schmierer; Jette Frederiksen; Achim Gass; Hugo Gama; Charles P Tilbery; Antonio J Rocha; José Flores; Frederik Barkhof; Alexandra Seewann; Jacqueline Palace; Tarek Yousry; Xavier Montalban; Christian Enzinger; Franz Fazekas
Journal:  J Neurol       Date:  2013-04-26       Impact factor: 4.849

Review 5.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

6.  Variant of multiple sclerosis with dementia and tumefactive demyelinating brain lesions.

Authors:  Sherifa A Hamed
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

7.  Development of a standardized MRI scoring tool for CNS demyelination in children.

Authors:  L H Verhey; H M Branson; S Laughlin; M M Shroff; S M Benseler; B M Feldman; D L Streiner; J G Sled; B Banwell
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-24       Impact factor: 3.825

8.  Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.

Authors:  Masaki Kobayashi; Yuko Shimizu; Noriyuki Shibata; Shinichiro Uchiyama
Journal:  J Neurol       Date:  2014-07-18       Impact factor: 4.849

9.  Fulminant demyelinating diseases.

Authors:  Megan R Rahmlow; Orhun Kantarci
Journal:  Neurohospitalist       Date:  2013-04

10.  Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms.

Authors:  Xuling Lin; Wai-Yung Yu; Lishya Liauw; Russell Jude Chander; Weiling E Soon; Hwei Yee Lee; Kevin Tan
Journal:  Neurol Clin Pract       Date:  2017-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.